Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000179889 | SCV000232206 | uncertain significance | not provided | 2018-07-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000690356 | SCV000818038 | likely benign | Peroxisome biogenesis disorder, complementation group K | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764928 | SCV000896100 | uncertain significance | Peroxisome biogenesis disorder 13A (Zellweger) | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002516805 | SCV003544507 | uncertain significance | Inborn genetic diseases | 2021-07-15 | criteria provided, single submitter | clinical testing | The c.575C>G (p.A192G) alteration is located in exon 7 (coding exon 7) of the PEX14 gene. This alteration results from a C to G substitution at nucleotide position 575, causing the alanine (A) at amino acid position 192 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003917676 | SCV004743869 | uncertain significance | PEX14-related disorder | 2023-12-08 | no assertion criteria provided | clinical testing | The PEX14 c.575C>G variant is predicted to result in the amino acid substitution p.Ala192Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.11% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |